Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) vs Xospata (gilteritinib)
Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) vs Xospata (gilteritinib)
Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) is an asparagine-specific enzyme used to treat acute lymphoblastic leukemia (ALL) in patients who have developed hypersensitivity to E. coli-derived asparaginase. Xospata (gilteritinib) is a tyrosine kinase inhibitor specifically designed to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. The choice between Rylaze and Xospata would depend on the specific type of leukemia a patient has and whether there is a presence of a FLT3 mutation in the case of AML, as these medications are not interchangeable and target different forms of leukemia.
Difference between Rylaze and Xospata
| Metric | Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) | Xospata (gilteritinib) |
|---|---|---|
| Generic name | Asparaginase erwinia chrysanthemi (recombinant)-rywn | Gilteritinib |
| Indications | Acute lymphoblastic leukemia (ALL) | Acute myeloid leukemia (AML) with FLT3 mutation |
| Mechanism of action | Enzyme that breaks down asparagine, depriving leukemia cells of an essential amino acid for protein synthesis | Tyrosine kinase inhibitor that targets FLT3/AXL receptors, inhibiting the growth of cancer cells |
| Brand names | Rylaze | Xospata |
| Administrative route | Intramuscular injection | Oral |
| Side effects | Allergic reactions, pancreatitis, glucose intolerance, thrombosis, bleeding, liver toxicity, etc. | Myalgia, fatigue, fever, dyspnea, edema, rash, diarrhea, nausea, etc. |
| Contraindications | History of serious hypersensitivity to asparaginase, pancreatitis, serious thrombosis, serious hemorrhagic events | QT prolongation, hypersensitivity to gilteritinib |
| Drug class | Antineoplastic enzyme | Tyrosine kinase inhibitor |
| Manufacturer | Jazz Pharmaceuticals | Astellas Pharma |
Efficacy
Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Efficacy in Leukemia
Rylaze, also known as asparaginase erwinia chrysanthemi (recombinant)-rywn, is a medication used in the treatment of acute lymphoblastic leukemia (ALL) in patients who have developed hypersensitivity to E. coli-derived asparaginase. It is designed to deprive leukemia cells of the amino acid asparagine, which is essential for their growth and survival. Clinical trials have demonstrated that Rylaze is effective in maintaining therapeutic levels of asparaginase activity when used as a component of a multi-agent chemotherapeutic regimen. Its efficacy is particularly crucial for patients who cannot tolerate other forms of asparaginase due to allergic reactions.
Xospata (gilteritinib) Efficacy in Leukemia
Xospata, known generically as gilteritinib, is an oral medication approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. Gilteritinib is a targeted therapy that inhibits the FLT3 gene mutation, which is found in approximately 30% of AML patients and is associated with a poor prognosis. Clinical studies have shown that Xospata can induce remission in a significant proportion of patients with FLT3 mutation-positive AML. The drug has been associated with improved overall survival compared to chemotherapy in this patient population.
Both Rylaze and Xospata represent important advancements in the treatment of different types of leukemia. Rylaze offers an alternative for ALL patients with hypersensitivity to other asparaginase products, while Xospata provides a targeted therapy option for AML patients with a specific genetic mutation. The efficacy of these drugs underscores the importance of personalized medicine and the development of treatments tailored to the unique genetic profiles of individual patients' leukemias.
It is important to note that the efficacy of Rylaze and Xospata can vary among patients, and their use should be based on a comprehensive evaluation of the patient's condition and genetic makeup. Healthcare providers should follow the latest clinical guidelines and consider the most current research findings when prescribing these medications for leukemia treatment.
Regulatory Agency Approvals
Rylaze
-
Food and Drug Administration (FDA), USA
Xospata
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
Access Rylaze or Xospata today
If Rylaze or Xospata are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us